Method of using haptenized ovarian carcinoma tumor cells
AssigneeThomas Jefferson University
InventorDavid Berd
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and methods of treating cancer. The compositions of the present invention include a composition prepared from a tumor cell which is hapten modified and syngeneic to the type of tumor to be treated. The composition has the properties, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of said human, of eliciting an inflammatory immune response against the tumor of said human, and of eliciting a delayed-type hypersensitivity response to the tumor of said human. The methods of the present invention are directed to treating cancer comprising administering a therapeutically effective amount of a composition comprising a tumor cell.
Claims8
A method of treating a human patient suffering from ovarian carcinoma, which method comprises administering to a patient having ovarian carcinoma a therapeutically effective amount of autologous human ovarian carcinoma tumor cells conjugated with hapten at ε-amino groups of lysine or —COOH groups, wherein the tumor cells have been treated to not grow and divide after administration to a subject, and an adjuvant, thereby eliciting a response to non-haptenized ovarian carcinoma tumor cells, and treating the ovarian carcinoma.
The miethiod according to ciaim 2, wherein the hapten is dinitroplienyl.
Dependencies are inferred from the claim text.